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indicator of the influence of the UK in global RW research. METHODS: All 1455
abstracts presented at the ISPOR 14th Annual European Congress in Madrid, Spain
in 2011 were reviewed in THE ISPOR OUTCOMES RESEARCH DIGEST, available via
the ISPOR website. Posters were also reviewed where available. Those reporting RW
studies were classified according to: therapeutic area, type of study, setting, source
of data and methodology, country undertaken, country of authors and involve-
ment of commercial sponsors. RESULTS: A total of 278 abstracts (19%) described
RW studies. Data were derived from a database in 55.8%, health service/patient
medical records in 24.8%, surveys/questionnaires in 15.8% and other sources in
3.6%. 12% were conducted in the UK; a further 8% included UK centres in an inter-
national study. 24% were conducted in the USA, 53% in another country (not UK,
not USA – 38 countries, most commonly Spain 6%, Canada 5%, Germany 5%, France
5%, The Netherlands 3% and Italy 3%) and 3% were international without a UK
centre. In 21% of abstracts there was a UK author. CONCLUSIONS: RW studies
presented at the ISPOR European Congress 2011 were most often single country
rather than international with the USA being the most prolific source. Of the rest,
the UK was the source of RW data in twice as many studies as any other country,
lending weight to the opinion that the UK provides an excellent environment for
conducting RW studies.
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OBJECTIVES: It is widely recognized that regular exercise improves fitness, with
increasing evidence that physical activity (PA; movement resulting in elevated
energy expenditure beyond basal levels) can affect health, particularly in chronic
disease. While pharmacologic therapy and exercise training have been shown to
improve capacity, persistent increase in PA requires behavior change. This review
examined studies testing the effectiveness of behavioral interventions to increase
PA in adults with chronic disease. METHODS: Embase and PubMed searches of
intervention studies published in English, 1995-2011. Inclusion criteria: Adults 45
years; COPD, diabetes, heart failure, obesity; exercise or PA endpoint; behavioral
intervention described in sufficient detail to permit interpretation. RESULTS: A
total of 932 abstracts screened; 169 articles retrieved; 36 reviewed. Most were ran-
domized trials (n30, 83%) with 2 intervention arms (n29, 81%), medium to high
quality (n34, 94%). Subjects were recruited through clinical settings (n28, 78%),
with disease severity a primary eligibility criterion (n23, 64%); 15 (42%) had sam-
ple sizes 40-100. Mean study duration  9.6 months (range: 1-84). Exercise inter-
vention: 30-50 minutes aerobic activity 3-5 times/week (n22, 61%); 64% included
walking. Instruction was individual (n25, 69%), initially supervised (n24, 67%)
followed by unsupervised home exercise (n15, 42%). Behavioral intervention:
counseling (n19, 53%) with personal contact follow-up (n12, 33%). Control
group: exercise without behavioral intervention (n14, 39%) or usual care (n15,
42%). Significant effects of the intervention were reported in 15 of 25 (60%) studies
testing exercise capacity (6-minute walk, cycle or treadmill), 19 of 26 (73%) testing
PA outcomes (pedometer, activity log, questionnaire), 11 of 22 (50%) measuring
HRQL, and 8 of 13 (62%) capturing behavioral endpoints. CONCLUSIONS: This re-
view provides insight into the range of designs, interventions, and outcome mea-
sures used in studies testing methods to improve PA in chronic disease. Results
identify promising interventions, with implications for improving research meth-
ods and outcomes.
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OBJECTIVES: Guidelines for treatment of rheumatoid arthritis (RA) advise initial
therapy with non-biological disease modifying antirheumatic drugs (DMARDs). In
case patients do not respond adequately, treatment should be switched to biologic
DMARDs. Aim of this research is to compare results of public available systematic
reviews (SRs) on comparative effectiveness (CER) and potential impact of differ-
ences in methodology. METHODS: We performed literature research for SR on CER
of biologics for the treatment of RA. Search was limited to reviews published in
2009 or later. Methods of the reviews and results were extracted from the publica-
tions. Results are summarized in narrative way and differences in results are re-
flected focusing on methodological key issues. RESULTS: Eleven recent SRs were
identified addressing the question of CER of biologics. Since there are no head-to-
head comparisons available for all but one biologic, reviews had to use indirect
comparisons to assess CER. Authors used the Simon-Bucher approach or Bayesian
methods (mixed treatment comparisons). Clinical trial guidelines for RA give the
advice to use Response Criteria defined according to the American College of Rheu-
matology (ACR) as primary parameter. Therefore, all trials assessed ACR20 (20%
improvement), ACR50 and ACR70 and could be used for comparison. Further pa-
rameters were not assessed in a uniform manner (e.g. quality of life) or not as-
sessed in all trials (e.g. disease activity score) and therefore could not be used for
indirect comparison of treatments. CONCLUSIONS: Due to lack of head-to-head
data for comparison of biologics, statistical methods for indirect comparison have
to be used to answer the question of CER. These methods have restrictions and base
on assumptions that might be heavily violated. Substances were tested over a time
period of more than 10 years with effects on study population and variation in
study designs. Nevertheless, the results seem to be fairly consistent.
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OBJECTIVES:Clostridium difficileinfection (CDI) has been found to be associated with
increased inpatient length of stay (LoS), however the causal direction is unclear.
Many have attempted to correct for potential endogeneity bias by case matching
patients at the hospital level or by using instrumental variable regressions. We
propose an alternative method using propensity score matching on a nationwide
dataset to isolate the added effect of the disease using hospital level data.
METHODS: Using the Hospital Episode Statistics (HES) dataset for England, four
propensity scoring techniques were tested to estimate the causal effect of CDI on
LoS of patients over 50 years old, who have been diagnosed with diabetes, chronic
obstructive pulmonary disorder (COPD), heart failure, and/or chronic kidney dis-
ease. Methodological variations include radius matching, nearest neighbour
matching with and without replacement, and kernel matching. RESULTS: Control-
ling for a number of covariates, nearest neighbour matching with replacement
produces the least biased and most consistent estimates at 15.22 days longer LoS
after contracting CDI, with a post-matching pseudo-R2value of zero and a mean
absolute standardized bias of 0.51% compared to 41.53% before matching. Radius
matching produces less consistent results at 17.05 days, with a mean standardized
bias of 2.93% after matching. Kernel matching does not adequately account for bias
likely due to the largely unbalanced nature of the treatment versus control group.
CONCLUSIONS: Propensity score matching serves as an alternative method to tra-
ditional regression approaches to estimate the causal effect of CDI on patient LoS.
The results are consistent with those previously derived in the literature and dem-
onstrate the heavy burden of CDI on the English National Health Service.
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OBJECTIVES: Veterans Administration Corporate Data Warehouse stores data-
bases with standardized structure that could be used for automated data extrac-
tion, reviewer abstraction, and text mining to determine the association between
health outcomes and disease-specific factors. This retrospective study provides
assessment of VA administrative data used to examine the impact of pharmaco-
logical therapy on complications in ulcerative colitis (UC). METHODS: Previous
studies investigating the effect of 5ASA on the risk for colorectal cancer (CRC) in UC
patients have reported conflicting results. We obtained nationwide UC and CRC
data from VA health care system for the period 2001-2011. Secondary relational
databases were searched for clinical variables based on standardized criteria - ICD9
diagnoses, procedural and medication codes. Data extraction captured demo-
graphics, clinical information and pharmacy record for a cohort of 37,191 UC cases.
We constructed a dataset of potential ulcerative colitis cases with CRC (n1,087)
defined by ICD9 codes 556.x for UC, and 153.x,154.x and 159.0 for CRC. A random
subsample of 100 non-5ASA users with CRC was compared to 100 controls without
CRC. RESULTS: Diagnosis of ICD9 code for CRC had PPV 79% and NPV 100% in the
random sample. Within the 1087 potential CRC cases, only 500 (46%) were found to
have evidence of both conditions on chart review with kappa agreement between
automated and manual abstraction 0.73 (95% CI: 0.70-0.76) for CRC and significantly
lower for UC - 0.60 (95% CI: 0.57-0.63). The initial overall prevalence of CRC in the UC
cohort was 2.9% and decreased to 1.34% after human text search verification.
CONCLUSIONS: Automated extracts have great potential for diseases surveillance
but manual review yields more reliable data. Pre-defined diagnostic algorithms
based on a combination of methods as well as further technology development like
natural language processing and longitudinal patient record will improve accuracy
of retrospective databases.
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OBJECTIVES: Real-world data is considered to be the gold standard by decision
makers to inform on cost-effectiveness of new drugs. Unfortunately real-world
data are often lacking in important parameters needed to inform on cost-effective-
ness, and RCT data can be used to address this problem. Illustrated by two cases
this abstract will show that the manner in which RCT and real-world data are
combined can have a profound influence on the resulting ICER. METHODS: Two
case studies in which real-world data on cetuximab for the indication of locally
advanced head and neck cancer and panitumumab for the indication of chemo-
refractory metastatic colorectal cancer was collected retrospectively served as
examples. RESULTS: The problem: In the case of cetuximab, patient selection in
daily practice resulted in too much disparity in baseline characteristics between
the treated and control group. The solution: survival data for both treatment
groups from the pivotal RCT was used and corrected according to the results seen
in the real-world data to better represent survival in daily practice. Using unad-
justed RCT data resulted in a difference of approximately 5,000 euro/QALY in the
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